Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 known ✓ | P30542 | 3/20 | 0.78 |
| ▸ | ADORA3 known ✓ | P0DMS8 | 1/20 | 0.78 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.78 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.78 |
| ▸ | P2RY2 | P41231 | 4/20 | 0.80 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | DPP4 | P27487 | 1/20 | 0.78 |
| ▸ | MEN1 | O00255 | 1/20 | 0.78 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.78 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.78 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.78 |
| ▸ | GAPDH | P04406 | 1/20 | 0.78 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.78 |
| ▸ | STAT6 | P42226 | 1/20 | 0.78 |
| ▸ | PI4KA | P42356 | 1/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.78 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.78 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.78 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.78 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adenosine SCHEMBL459770 | 1.00 | P2RY2 (0.80) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Adenosine SCHEMBL28240733 | 1.00 | P2RY2 (0.80) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Adenosine SCHEMBL29362201 | 1.00 | P2RY2 (0.80) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Adenosine SCHEMBL9225148 | 0.99 | P2RY2 (0.79) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Adenosine SCHEMBL29397260 | 0.99 | P2RY2 (0.82) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Vidarabine SCHEMBL7170349 | 0.99 | P2RY2 (0.82) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Adenosine SCHEMBL1744580 | 0.99 | P2RY2 (0.82) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Adenosine SCHEMBL2210868 | 0.99 | P2RY2 (0.82) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Adenosine SCHEMBL29796534 | 0.99 | P2RY2 (0.82) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 | |
| Adenosine SCHEMBL28296801 | 0.98 | P2RY2 (0.80) | P2RY2SMN1; SMN2ADORA1DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112881311-B | Creatine kinase detection reagent, kit and detection method | 深圳迈瑞生物医疗电子股份有限公司 | 2025-05-30 | — | — | CN | claimed |
| CN-112881311-A | Creatine kinase detection reagent, kit and detection method | 深圳迈瑞生物医疗电子股份有限公司 | 2021-06-01 | — | — | CN | claimed |
| US-8608922-B2 | Biosensor for continuous monitoring of metabolites and proteins and methods of manufacture thereof | THE UNIVERSITY OF CONNECTICUT (US) | 2013-12-17 | — | — | US | claimed |
| WO-2011133580-A1 | USE OF DRUGS THAT ACTIVATE P2Y RECEPTORS TO ENHANCE SYNAPTOGENESIS | BACK BAY SCIENTIFIC LLC (US) | 2011-10-27 | — | — | WO | claimed |
| US-20110257109-A1 | USE OF DRUGS THAT ACTIVATE P2Y RECEPTORS TO ENHANCE SYNAPTOGENESIS | BACK BAY SCIENTIFIC, LLC | 2011-10-20 | — | — | US | claimed |
| US-20100116691-A1 | BIOSENSOR FOR CONTINUOUS MONITORING OF METABOLITES AND PROTEINS AND METHODS OF MANUFACTURE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2010-05-13 | — | — | US | claimed |
| US-20050053612-A1 | Nucleotide regulation of immune responses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-03-10 | — | — | US | claimed |
| EP-0969848-A1 | USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE | Clemson University (US) | 2000-01-12 | — | — | EP | claimed |
| WO-1998030222-A1 | USE OF DIADENOSINE POLYPHOSPHATES FOR REDUCING BLOOD PRESSURE | CLEMSON UNIVERSITY (US) | 1998-07-16 | — | — | WO | claimed |
| EP-0721986-A2 | Creatine kinase reagent | WAKO PURE CHEMICAL INDUSTRIES LTD (JP) | 1996-07-17 | — | — | EP | claimed |
| US-5009994-A | Uniform distribution | EM DIAGNOSTIC SYSTEMS, INC. (US) | 1991-04-23 | — | — | US | claimed |
| US-4810639-A | CREATINE KINASE ISOENZYMES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1989-03-07 | — | — | US | claimed |
| EP-0227440-A2 | Immunoassay for creatine kinase MB using bound and soluble antibodies | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-07-01 | — | — | EP | claimed |
| EP-0015437-B1 | METHOD AND REAGENT FOR THE DETERMINATION OF CREATINE KINASE | Roche Diagnostics GmbH (DE) | 1981-11-25 | — | — | EP | claimed |
| EP-0008341-B1 | METHOD AND REAGENT FOR ENZYMATIC DETERMINATIONS AND TEST KIT FOR THIS METHOD | Roche Diagnostics GmbH (DE) | 1981-11-04 | — | — | EP | claimed |
| US-4286057-A | QUANTITATIVE ANALYSIS OF CREATINE KINASE USING THE LUMINESCENT SYSTEM OF THE FIREFLY | BOEHRINGER MANNHEIM GMBH (DE) | 1981-08-25 | — | — | US | claimed |
| US-4235961-A | Method for photometric determination of the subunit B of creatine kinase and a reagent for carrying out the method | LKB-PRODUKTER AB (SE) | 1980-11-25 | — | — | US | claimed |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | ASTROCYTE PHARMACEUTICALS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-4235961-A | Method for photometric determination of the subunit B of creatine kinase and a reagent for carrying out the method | LKB-PRODUKTER AB (SE) | 1980-11-25 | — | — | US | disclosed |
| US-4220714-A | ADENOSINE 5*-MONOPHOSPHATE AND POTASSIUM FLUORIDE | ISTITUTO SIEROTERAPICO E VACCINOGENO TOSCANO SCLAVO S.P.A. (IT) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050053612-A1 | Nucleotide regulation of immune responses | NT5C2, ENTPD5, ENTPD1 | ADORA1 12/4885ADORA3 11/4885ADORA2A 6/4885 |
| US-20250345353-A1 | COMPOUNDS AND METHODS FOR TREATING NEUROLOGICAL AND CARDIOVASCULAR CONDITIONS | TNNI3, CPT1B, TNNT2 | ADORA1 994/4885ADORA3 778/4885ADORA2A 436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.